Answers are grounded in this paper and cite their sources.
Rituximab is a monoclonal antibody that was first approved by the FDA as an antineoplastic agent designed to treat B-cell malignancies. This article will review the mechanism of action and clinical role of this anti-B-cell agent.
No takes yet. Share an insight, caveat, or question.
Selewski et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: